IMCD US Pharma expands with DuPont in US Nutra Market

ROTTERDAM, The Netherlands (23 October 2018) – IMCD US Pharma and DuPont Nutrition & Health are pleased to announce an expansion of their distribution partnership in the United States Nutraceutical industries for a portion of DuPont’s Pharmaceutical Excipients including, AVICEL®, ENDURANCE®, ACCELERATE®, and AC-DI-SOL®.

ROTTERDAM, The Netherlands (23 October 2018) – IMCD US Pharma and DuPont Nutrition & Health are pleased to announce an expansion of their distribution partnership in the United States Nutraceutical industries for a portion of DuPont’s Pharmaceutical Excipients including, AVICEL®, ENDURANCE®, ACCELERATE®, and AC-DI-SOL®. This expansion furthers the 56-year partnership and strengthens both IMCD’s extensive portfolio as well as DuPont Nutrition & Health’s route to market.

IMCD US Pharma, previously Mutchler Inc., has been serving the pharmaceutical industry since 1947. Combined with the recent acquisition of ET Horn (established in 1961), IMCD provides nationwide formulation expertise and solutions to the nutraceutical & pharmaceutical segments through a team of dedicated specialists and a technical application center.

"I am pleased to announce the extension of our global partnership with IMCD to now include the US Nutraceutical market,” says Chris Poppe, North American Segment Manager, DuPont Health & Nutrition. “IMCD's experience and technical expertise positions them well to support and develop our customers, helping them to grow their business with innovative excipient solutions."

Neil Houston, Director Pharmaceuticals Americas, IMCD US Pharma commented: "We are delighted to add DuPont's prestigious range of excipients to our product offering. The combination of our dedicated nutraceutical specialists and the application center in New Jersey will provide an unrivalled source of formulation expertise and new product concepts."